Related Experiment Videos
Coagulation abnormalities in patients undergoing myocardial revascularization
Insights
This study on 100 patients found that screening for hypercoagulability and treating abnormalities with anticoagulants improved vein graft patency and reduced pulmonary embolism. Some patients achieved lifelong freedom from anticoagulant therapy.
Area of Science:
- Vascular Surgery
- Hematology
- Cardiovascular Research
Background:
- Hypercoagulability, a state of increased tendency to form blood clots, is a significant concern in patients undergoing vascular surgery.
- Preoperative and postoperative monitoring of coagulation status is crucial for managing thrombotic risks.
- Understanding the specific coagulation abnormalities can guide targeted anticoagulant therapy.
Purpose of the Study:
- To investigate the incidence of hypercoagulability in patients undergoing vascular surgery.
- To evaluate the efficacy of anticoagulant therapy in managing hypercoagulability and its impact on clinical outcomes.
- To assess the long-term effects of anticoagulant treatment on vein graft patency and thromboembolic events.
Main Methods:
- Screening 100 patients for hypercoagulability preoperatively and at multiple time points postoperatively.
- Administering anticoagulants (heparin, aspirin, Coumadin) based on the presence and timing of coagulation abnormalities.
- Continuing lifelong anticoagulation for preoperative abnormalities and 6-month treatment for postoperative ones before cardiac catheterization.
Main Results:
- Twenty-four percent of patients had no coagulation abnormalities.
- Fifteen patients exhibited preoperative hypercoagulability, primarily low antithrombin III activity.
- Sixty-one patients developed postoperative hypercoagulability, characterized by increased thrombin generation and platelet adhesiveness.
Conclusions:
- Anticoagulant therapy in hypercoagulable patients led to a decreased incidence of pulmonary embolism.
- Vein graft patency was observed to increase in the treated group.
- Twenty-four percent of patients were successfully weaned off anticoagulant therapy, indicating potential for personalized treatment strategies.
Abstract:
One hundred patients were screened for hypercoagulability preoperatively and on the third, seventh, tenth, fourteenth, and twenty-first days postoperatively. Patients found to have hypercoagulability were treated with heparin, aspirin, and Coumadin. When the abnormality was present preoperatively, treatment was continued for the duration of the patient's life. Those patients in whom abnormalities developed postoperatively were given anticoagulants until cardiac catheterization 6 months following their operation. Twenty-four of the 100 patients had no coagulation abnormalities preoperatively or postoperatively. Fifteen patients were found to have abnormality prior to operation. Their predominant abnormality was low antithrombin III activity. Sixty-one patients became hypercoagulable postoperatively. Predominant abnormality in this group of patients was increased thrombin generation and increased platelet adhesiveness. Evaluation of patients in this study group revealed a decrease in the incidence of pulmonary embolism, an increase in the patency of vein grafts, and the elimination of anticoagulant therapy in 24 percent of the patients.